Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06250959
PHASE2

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

Sponsor: Chen Suning

View on ClinicalTrials.gov

Summary

In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.

Official title: Comparing the Efficacy and Safety of Reduced-dose Chemotherapy Followed by Blinatumomab Versus hyperCVAD as Induction Therapy for Newly Diagnosed Ph-negative B-ALL: a Multicenter, Radomized, Phase 2 Study

Key Details

Gender

All

Age Range

15 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

124

Start Date

2024-02-05

Completion Date

2026-12-31

Last Updated

2024-04-04

Healthy Volunteers

No

Interventions

DRUG

Blinatumomab Injection [Blincyto]

Reduced-intensity chemotherapy followed by Blinatumomab

DRUG

Doxorubicin

HyperCVAD regimen

Locations (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China